AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.2 |
Market Cap | 2.34M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 5571.72 |
PE Ratio (ttm) | 0 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 3.5 |
Volume | 161,929 |
Avg. Volume (20D) | 58,505 |
Open | 3.50 |
Previous Close | 3.18 |
Day's Range | 3.15 - 3.50 |
52-Week Range | 2.66 - 152.79 |
Beta | undefined |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
Analyst Forecast
According to 1 analyst ratings, the average rating for RNAZ stock is "Strong Buy." The 12-month stock price forecast is $20, which is an increase of 496.20% from the latest price.
8 months ago · https://www.defenseworld.net
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by AnalystTransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeuti...
1 year ago · proactiveinvestors.com
Transcode Therapeutic stock whipsaws lower after cut price placingTransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-...
1 year ago · proactiveinvestors.com
TransCode Therapeutics stock skyrockets on positive brain cancer trial resultsTransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tu...